PXT3003 long-term open-label extension in Charcot-Marie-Tooth disease type 1A

Phase 3, open-label trial of PXT 3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) and Charcot-Marie-Tooth disease (CMT) (5 arms), sponsored by Pharnext. Primary endpoints: Incidence of treatment-emergent adverse events related to investigational product and Incidence of treatment-emergent adverse events related to investigational product after Visit 9. Started Jan 2018; status: completed.